CoChat

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

Open access
Miyake, Teruki, Yoshida, Sakiko, Furukawa, Shinya, Sakai, Takenori, Tada, Fujimasa, Senba, Hidenori, Yamamoto, Shin, Koizumi, Yohei, Yoshida, Osamu, Hirooka, Masashi, Kumagi, Teru, Niiya, Tetsuju, Miyaoka, Hiroaki, Masanori, Abe, Matsuura, Bunzo, Hiasa, Yoichi · 2018 · Open Medicine
Cited by 48

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 diabetes mellitus (T2DM) complicated by non-alcoholic fatty liver disease (NAFLD). Methods: We prospectively enrolled patients with T2DM complicated by NAFLD treated at our institutions from January 2015 to December 2016. Patients received oral ipragliflozin (50 mg/day) once daily for 24 weeks. Body composition was evaluated using an InBody720 analyzer. We used transient elastography to measure liver stiffness and the controlled attenuation parameter for the quantification of liver steatosis in patients with NASH. Results: Forty-three patients with T2DM and NAFLD were enrolled (12 with biopsy-proven NASH and 31 with NAFLD diagnosed by ultrasonography). After 24 weeks, body weight, hemoglobin A1c (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase, body fat mass, and steatosis were significantly decreased compared to baseline measurements in patients with NASH. However, muscle mass was not reduced, and liver stiffness showed a statistically insignificant tendency to decrease. NAFLD patients also showed a significant reduction in body weight, HbA1c, AST, and ALT compared to baseline measurements. Conclusion: Ipragliflozin may be effective in patients with T2DM complicated by NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1515/med-2018-0059

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 48

Metadata

Authors
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., Kumagi, T., Niiya, T., Miyaoka, H., Masanori, A., Matsuura, B., & Hiasa, Y.
Venue
Open Medicine
Published
2018-01-01
Volume
13
Issue
1
Pages
402-409
ISSN
  • 1895-1058 (ISSN-L)
  • 2391-5463
OpenAlex
W2890275564
Cited by
48
References
2
FWCI
4.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1515/med-2018-0059
The paper
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., Kumagi, T., Niiya, T., Miyaoka, H., Masanori, A., Matsuura, B., & Hiasa, Y. (2018). Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Medicine. https://doi.org/10.1515/med-2018-0059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.